Alteogen Signs $365m Hybrozyme Licensing Deal with Pharma Company
4 Articles
4 Articles
Alteogen has signed an additional technology export agreement for its subcutaneous (SC) formulation conversion platform technology. On the 5th, Alteogen announced that it had signed an exclusive license agreement with a global pharmaceutical company for the development and commercialization of SC formulations of biopharmaceuticals utilizing its Hybrozyme platform technology. Alteogen did not disclose the counterparty or the product name in accor…
(Seoul = Yonhap News) Reporter Shin Seon-mi = Alteogen [196170] has signed a license agreement worth up to $365 million (approximately 521.9 billion won) with a global pharmaceutical company ...
Verdict Hospital
Pharmaceutical Business reviewAlteogen signs $365m Hybrozyme licensing deal with pharma company
Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.The post Alteogen signs $365m Hybrozyme licensing deal with pharma company appeared first on Hospital Management.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
